Heidelberg Pharma and Magenta Therapeutics Sign Exclusive Multi-Target Research Agreement

06-Mar-2018 - Heidelberg Pharma AG and Magenta Therapeutics Inc., a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, announced the signing of an exclusive multi-target research agreement. Heidelberg Pharma Research GmbH signed ...

WILEX signs antibody license agreement with Telix Pharmaceuticals Limited

18-Jan-2017 - WILEX AG and Australian biopharmaceutical company Telix Pharmaceuticals Limited, announced that they have concluded a worldwide license agreement for the development and commercialization of the imaging agent REDECTANE®, a radiolabeled form of the monoclonal antibody Girentuximab. Girentuximab ...

Subsidiary Heidelberg Pharma contracts Celonic

Contract contains antibody cell line development and antibody production

28-Sep-2016 - WILEX AG, announced that its subsidiary Heidelberg Pharma, has signed an agreement with Celonic AG, Basel, Switzerland, a specialist in the development and manufacturing of biologics (CDMO). This agreement includes cell line development and the production of non-GMP and GMP (Good Manufacturing ...

WILEX AG plans change on the Supervisory Board

08-Apr-2016 - WILEX AG announced its plan to reduce the number of Supervisory Board members from six to five. Long-standing member Andreas Krebs will step down from the Supervisory Board at his own request for professional reasons after this year’s Annual General Meeting. Mr Krebs has been a member of the ...

WILEX subsidiary Heidelberg Pharma extends research collaboration with Roche

16-Oct-2014 - WILEX AG announced that WILEX subsidiary Heidelberg Pharma and Roche extended the existing 2013 licence agreement to apply the antibody drug conjugate (ADC) technology for the further development of Roche antibodies. The aim is to identify and develop novel AntibodyTargeted Amanitin Conjugates ...

UCB strengthens strategic alliance with WILEX

UCB's position as a strategic investor now represents 18% of WILEX shares

10-Jun-2010 - UCB has acquired an additional 6.65% of shares in WILEX which increases its total holding to 18.05%. The five oncology projects which WILEX acquired from UCB in early 2009 are making good progress with one project, the MEK inhibitor WX554, now in clinical development Phase I. "WILEX is the ...

Wilex' REDECTANE meets both endpoints specificity and sensitivity with superiority over CT in its pivotal Phase III trial

20-May-2010 - WILEX AG and IBA (Ion Beam Applications SA) announced that the final results of the pivotal phase III registration trial REDECT have been received. The results of the study demonstrate that PET/CT with REDECTANE(R) lead to a significantly improved diagnosis in comparison to CT alone. The aim of ...

UCB and WILEX to enter into strategic alliance to develop UCB's preclinical oncology portfolio

UCB to become a strategic investor in WILEX

12-Jan-2009 - UCB Pharma S.A. (UCB) and WILEX AG announced that they have agreed to enter into a strategic partnership. WILEX will acquire world-wide rights to develop UCB's entire preclinical oncology portfolio, comprising two small-molecule programmes and three antibody programmes. UCB retains exclusive ...

Wilex enters into manufacturing and distribution agreement with IBA Molecular

18-Dec-2006 - Wilex AG signed a contract with IBA Molecular N.A., Sterling, Virginia, USA. IBA delivers radiopharmaceuticals and isotopes for radiotherapy and radiodiagnosis. IBA will label the Wilex antibody WX-G250 with 124Iodine and will deliver it to the study centres participating in the pivotal trial for ...

Change in Senior Management of WILEX AG

21-Jun-2006 - WILEX AG announced a change in the senior management of the company. Mr. Peter Llewellyn-Davies was appointed acting Chief Financial Officer of the company as of June 15, 2006. Mr. Llewellyn-Davies, who will initially act as an advisor to WILEX, assumes the tasks of Mr. Niels Ackermann who ...